Contact Us

Web Copyright: Shijiazhuang No.4 Pharmaceutical Co., Ltd.    Powered by www.300.cn   冀ICP备05007979号-1

Add: No. 288,Zhujiang Road, High-tech Industrial

Development,Shijiazhuang, Hebei, China
Web: www.sjzsiyao.com
Tel: 86 311 67167137 / 67167144
E-mail:
trade@sjzsiyao.com / chinainfusion@163.com
Skype: xlmamary

About Us

Contact us!

Online Message

可信组件

NEWS CENTER

Shijiazhuang No. 4 Pharmaceutical Co., Ltd. is again ranking top 50 in China Chemical Drug R&D Strength
$info.title
Shijiazhuang No. 4 Pharmaceutical Co., Ltd. is ranking top 50 in China Chemical Drug R&D Strength Once Again On September 18, at the 2021 Conference on High Quality Development of Health Industry and the sixth Summit for China Pharmaceutical R&D Innovation (PDI) held in Chongqing, the list of 2021 Chinese Chemical pharmaceutical R&D Strength TOP100 was announced, and Shijiazhuang No. 4 Pharmaceutical Co., Ltd. ranked 44th, once again ranked among the top 50 chemical pharmaceutical R&D strength in China.     R&d investment is one of the important indicators of innovation capacity. According to Frost&Sullivan data, R&D investment of innovative pharmaceutical enterprises has continued to grow in the past five years. From 2016 to 2020, the total R&D investment in China has increased from 11.9 billion US dollars to 27 billion US dollars, with a compound annual growth rate of 22.7%.  Twenty-four companies on the list spent more than 500 million yuan on R&D in 2020, while eight spent more than 1 billion yuan on R&D.     With the policy implementation execute, the pharmaceutical industry market is facing a constant adjustment and differentiation, competitive situation from production as the core to research and development ability and drug innovation as the core, mainly on research and development of innovative enterprises will usher in unprecedented opportunities for development.  
API Dexmedetomidine Hydrochloride Manufactured by SSY Group was Approved
$info.title
API Dexmedetomidine Hydrochloride Manufactured by SSY Group was Approved  Recently API Dexmedetomidine Hydrochloride developed and applied by Hebei Guolong Pharmaceutical Co., Ltd., SSY Group was approved by NMPA to be used for the FPF. FPF Dexmedetomidine Hydrochloride Injection (2ml:0.2mg) applied by SSY Group also got the MA from NMPA and treated as consistency evaluation completion.  Dexmedetomidine is a α2 adrenergic receptor agonists, it is maily used for sedation during tracheal intubation and mechanical ventilation in patients undergoing surgery under general anesthesia.
Terbutalin Sulphate Nebuliser Solution MA is approved
$info.title
April 12, Shijiazhuang No. 4 Pharmaceutical Co., Ltd. gained the manufacture and registration approval of Terbutalin Sulfate Nebuliser Solution 2ml: 5mg from NMPA, it is viewed as consistency evaluaiton has been completed. Terbutalin Sulfate Nebuliser Solution is used for relief bronchospasm associate with bronchial asthma, chronic bronchitis, emphysema and other pulmonary diseases. It can only be administered though an atomizer, dilution is not in need.
Vice Governor Ge Haijiao visited Shijiazhuang No.4 Pharmaceutical to check the supply and security of anti-epidemic materials
$info.title
Vice Governor Ge Haijiao visited Shijiazhuang No.4 Pharmaceutical to check the supply and security of anti-epidemic materials
"Ciprofloxacin Lactate and Sodium Chloride Injection"has passed the evaluation of generic drug quality and efficacy consistency
$info.title
"Ciprofloxacin Lactate and Sodium Chloride Injection"has passed the evaluation of generic drug quality and efficacy consistency
Page up
1
2
3